Any current/future new fundraising through debt or equity?

The company plans to be conservative with cash usage. Priority for cash utilization will be on M&A opportunities and CAPEX. CAPEX planned for FY24 is around Rs. 500 to 600 crores. No explicit mention of new fundraising through debt or equity in the current quarters. Dividend payout decisions will be taken in the coming quarters based on cash position. The company is generating strong cash flows (Rs. 2,000+ crores from operations) with a healthy net cash position of Rs. 1,727 crores as of March 2023. No indication of immediate equity or debt issuance; focus remains on organic growth, CAPEX, and

Any current/future capex/capital investment/strategic investment?

The company has spent around Rs. 310 crores on the Udaipur plant, which is expected to be commercialized and capitalized in H1 FY24, leading to depreciation expenses in subsequent quarters. For FY24, planned CAPEX is around Rs. 550 to Rs. 600 crores. The Udaipur plant will house Dydrogesterone manufacturing, with no significant rise in OPEX expected. The company remains conservative with cash but prioritizes investments in good M&A opportunities. Excess cash generation (over Rs. 2,000 crores from operations) beyond CAPEX needs (Rs. 500-600 crores annually) is expected to be deployed strategica

Future growth expectations in sales/revenue/volumes?

Chronic segment expected to drive significant growth; chronic share reached all-time high of 36% with 17% growth this quarter, outperforming IPM growth of 10% by 1.7x. Consumer Healthcare segment projected to sustain strong growth, with 8% Q1 growth and historic CAGR of 22% (FY21-23). Aim to launch 15-20 new DMF-grade SKUs every quarter, targeting disruptive growth via high-quality, affordable medicines. Domestic business will continue contributing over 90% of revenues; export business remains a smaller portion with lower margins. Focus on volume-led growth through wide distribution and prescr

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA margins guidance for FY24 is maintained at 24% to 26% (Page 13, 7). Management is confident of maintaining or improving EBITDA margins beyond FY24 due to operating leverage and mix improvement (Page 7). Chronic segment share is increasing (36% in Q1 FY24 vs 28% in FY18), expected to outperform the market and drive higher margins (Page 6, 15). Volume-led growth with superior prescription-driven quality sales is sustainable and expected to continue (Page 5-6). PAT grew 66% YoY to Rs. 494 crore in Q1 FY24; EPS was Rs. 12.1 per share, with cash EPS at Rs. 14.3 (Page 7). CAPEX plan

Mankind Pharma LtdQ1 FY24Pharmaceuticals & Biotechnology

Mankind Pharma Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,469.3P/E: 47.8Market Cap: ₹1.0L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Chronic segment expected to drive significant growth; chronic share reached all-time high of 36% with 17% growth this quarter, outperforming IPM growth of 10% by 1.7x.
Consumer Healthcare segment projected to sustain strong growth, with 8% Q1 growth and historic CAGR of 22% (FY21-23).
Aim to launch 15-20 new DMF-grade SKUs every quarter, targeting disruptive growth via high-quality, affordable medicines.
Domestic business will continue contributing over 90% of revenues; export business remains a smaller portion with lower margins.
Focus on volume-led growth through wide distribution and prescription-led sales with 5 lakh doctors covered.
Expect to maintain EBITDA margins in the range of 24%-26%.
Continued investment in marketing and R&D to support leadership in chronic and Consumer Healthcare segments.
Overall volume growth in the domestic market significantly outpacing IPM growth (4.3% vs 1.4% in Q1).

Margin guidance

Category 3

EBITDA margins guidance for FY24 is maintained at 24% to 26% (Page 13, 7).
Management is confident of maintaining or improving EBITDA margins beyond FY24 due to operating leverage and mix improvement (Page 7).
Chronic segment share is increasing (36% in Q1 FY24 vs 28% in FY18), expected to outperform the market and drive higher margins (Page 6, 15).
Volume-led growth with superior prescription-driven quality sales is sustainable and expected to continue (Page 5-6).
PAT grew 66% YoY to Rs. 494 crore in Q1 FY24; EPS was Rs. 12.1 per share, with cash EPS at Rs. 14.3 (Page 7).
CAPEX planned in the range of Rs. 550-600 crore in FY24 supports growth ambitions (Page 7, 12).
Export business growth is opportunistic but domestic business will continue to contribute >90% revenues (Page 10, 15).

See what Mankind Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company plans to be conservative with cash usage.
Priority for cash utilization will be on M&A opportunities and CAPEX.
CAPEX planned for FY24 is around Rs. 500 to 600 crores.
No explicit mention of new fundraising through debt or equity in the current quarters.
Dividend payout decisions will be taken in the coming quarters based on cash position.
The company is generating strong cash flows (Rs. 2,000+ crores from operations) with a healthy net cash position of Rs. 1,727 crores as of March 2023.
No indication of immediate equity or debt issuance; focus remains on organic growth, CAPEX, and acquisitions using existing cash.

Order book

The transcript does not provide any specific information regarding the current or expected order book or pending orders for Mankind Pharma Limited in Q1 FY24. There are no mentions of order backlog, pending orders, or order book figures in the discussed content on page 15 or surrounding pages. The focus is mainly on financial results, growth in domestic and export revenues, chronic segment expansion, margins, and operational metrics.

See what Mankind Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has spent around Rs. 310 crores on the Udaipur plant, which is expected to be commercialized and capitalized in H1 FY24, leading to depreciation expenses in subsequent quarters.
For FY24, planned CAPEX is around Rs. 550 to Rs. 600 crores.
The Udaipur plant will house Dydrogesterone manufacturing, with no significant rise in OPEX expected.
The company remains conservative with cash but prioritizes investments in good M&A opportunities.
Excess cash generation (over Rs. 2,000 crores from operations) beyond CAPEX needs (Rs. 500-600 crores annually) is expected to be deployed strategically, possibly including acquisitions in Consumer Healthcare and chronic segments.

Track Mankind Pharma Ltd — get its next earnings analysis in your feed

How does Mankind Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMankind Pharma Ltd

Rev 3Mar 3

See where Mankind Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Mankind Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Mankind Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Mankind Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Mankind Pharma Ltd Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Mankind Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Mankind Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season